pharma · Retinitis Pigmentosa · Dyslipidaemia
HRA Pharma
Laboratoire HRA Pharma
Laboratoire HRA Pharma is a pharma organization headquartered in CHATILLON, FR. Primary therapeutic focus areas include Retinitis Pigmentosa, Dyslipidaemia, Hemophilia, Allergic Conjunctivitis, Leber congenital amaurosis
CHATILLON, USA HQ
121 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- CHATILLON, USA
- Employees
- 121
- Programs
- 11
- Drugs
- 17
- Patents
- 0
SB-421a-006
Phase 2 · small molecule · Retinitis Pigmentosa
SB-421a-006 for Retinitis Pigmentosa is a Phase 2 program (small_molecule) at Laboratoire HRA Pharma with 1 ClinicalTrials.gov record(s).
Internal code SB-421a-006
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Laboratoire HRA Pharma
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Retinitis Pigmentosa
- Status
- active
- Trials
- 1